Sign In
Buy OMI
$2.80
+0 (+0%)
At Close: Mar 30, 2026
Alcon (ALC) Expands in the U.S. With New Clareon IOLs Launch
03:47pm, Tuesday, 08'th Mar 2022 Zacks Investment Research
With the latest launch, Alcon's (ALC) Clarion Monofocal, Clareon PanOptix, Clareon PanOptix Toric, Clareon Vivity and Clareon Vivity Toric IOLs are now available in the United States.
Here's Why You Should Retain Chemed (CHE) Stock For Now
01:37pm, Tuesday, 08'th Mar 2022 Zacks Investment Research
Investors are optimistic about Chemed's (CHE) better-than-expected earnings and robust performance by the Roto-Rooter arm.
Here's Why You Should Retain SmileDirectClub (SDC) For Now
01:36pm, Tuesday, 08'th Mar 2022 Zacks Investment Research
Investors are optimistic about SmileDirectClub's (SDC) strategic collaborations and product launches.
ResMed's (RMD) SaaS Arm Strength Aids Growth, Supply Woes Stay
02:00pm, Monday, 07'th Mar 2022 Zacks Investment Research
ResMed's (RMD) growing focus to expand in the high-growth international markets is an added upside.
Medtronic (MDT) to Gain From New Reimbursement Program for CGM
01:47pm, Monday, 07'th Mar 2022 Zacks Investment Research
Ontario government's new comprehensive reimbursement program for CGM will enhance access to Medtronic's (MDT) integrated CGM technology for type 1 diabetes patients.
Bruker (BRKR) to Improve Spatial Biology With New Launch
03:02pm, Friday, 04'th Mar 2022 Zacks Investment Research
Bruker's (BRKR) acquired company, Canopy Biosciences, introduced its next generation of ChipCytometry instrumentation for spatial biology.
Bruker (BRKR), Newomics to Co-Market Joint MnESI-MS Platform
02:18pm, Thursday, 03'rd Mar 2022 Zacks Investment Research
The maxis II and timsTOF Pro 2 mass spectrometers from Bruker (BRKR) will be marketed with Newomics's MnESI product line.
Here's Why You Should Retain Haemonetics (HAE) Stock for Now
02:14pm, Thursday, 03'rd Mar 2022 Zacks Investment Research
Investors are optimistic about Haemonetics (HAE) given strong recovery across businesses and strength in plasma franchise.
McKesson (MCK) Up 5.1% Since Q3 Earnings: What's Driving It?
02:55pm, Wednesday, 02'nd Mar 2022 Zacks Investment Research
Investors are optimistic about McKesson's (MCK) robust segmental performance and raised earnings outlook for fiscal 2022.
Here's Why You Should Invest In Bruker (BRKR) Stock Now
02:17pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Investors are optimistic about Bruker's (BRKR) better-than-expected revenues and robust segmental performance.
Merger Arbitrage Mondays - Standard General Acquires Tegna For $8.6 billion Or $24 Per Share In Cash
03:25pm, Monday, 28'th Feb 2022 Benzinga
Merger activity remained steady with five new deals announced, four deals completed and one deal terminated. Two of the five new deals announced were potential deals in the works.
TEGNA Inc. (NYSE: TG
Are These Medical Stocks Undervalued Right Now?
02:40pm, Monday, 28'th Feb 2022 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Owens & Minor to Present at the J.P. Morgan High Yield & Leveraged Finance Conference Monday, February 28, 2022
10:12pm, Friday, 25'th Feb 2022
RICHMOND, Va.--(BUSINESS WIRE)--Owens and Minor to Present at the J.P. Morgan Global High Yield & Leveraged Finance Conference
Owens & Minor Selects Kenny Gardner to Join Board of Directors
11:45am, Thursday, 24'th Feb 2022 Kwhen Finance
Why Owens & Minor''s Shares Are Trading Higher Today
07:02pm, Wednesday, 23'rd Feb 2022 Benzinga
Owens & Minor Inc (NYSE: OMI ) has reported adjusted EPS of $0.81 in Q4 , lower than $1.14 a year ago but ahead of the consensus of $0.71. Revenue for the quarter increased 4.45% to $2.47 billion, better than the consensus estimate of $2.43 billion. Global Solutions segment revenue grew 3% to $2 billion due to strong performance in Patient Direct business combined with increased PPE sales, partially offset … Full story available on Benzinga.com
